### Sultanate of Oman Ministry of Health Directorate General of Pharmaceutical Affairs and Drug Control Muscat



سلطنة عُمان وزارة الصحة المديرية العامة للصيدلة والرقابة الدوائية مسقط

To:

THE DIRECTOR GENERAL OF HEALTH SERVICES IN ALL GOVERNORATES

Commanding Officer, Armed Forces Hospital (Al Khoudh & Salalah)

Director General of Engineering Affairs, MOH

**Director General of Royal Hospital** 

Director General of Khoula Hospital

**Director General of Medical Supplies (MOH)** 

Director General of Pvt. Health Est. Affairs (to kindly arrange distribution to all Pvt. Hospitals)

Hospital Director (Al Nahda Hospital)

Hospital Director (Al Massara Hospital)

The Head of Medical Services in SQU Hospital

The Head of Medical Services in Royal Oman Police

The Head of Medical Services in Ministry of Defence

The Head of Medical Services in The Diwan

The Head of Medical Services in The Sultan's Special Force

The Head of Medical Services in Internal Security Services

The Head of Medical Services in Petroleum Development of Oman

The Head of Medical Services in LNG Oman

ALL PRIVATE PHARMACIES & DRUG STORES

#### After Compliments,

Please find attached our Circular No 121 dated 13/6/23 Regarding NCMDR Field Safety Corrective Action of Calibration Serum Level 3, Human Precision Control Levels 2 & 3 and Human Assayed Multi-Sera Levels 2 & 3 from (mfr: Randox laboratories Ltd).

#### Copy to:

- Director, Office of H.E. The Undersecretary for Health Affairs
- Director of Medical Device Control, DGPA&DC
- Director of Pharmacovigilance & Drug Information Dept, DGPA&DC
- Director of Drug Control Department, DGPA&DC
- Director of Pharmaceutical Licensing Department, DGPA&DC
- Director of Central Quality Control Lab., DGPA&DC
- Supdt. of Central Drug Information





Sultanate of Oman Ministry of Health Directorate General of Pharmaceutical Affairs and Drug Control Muscat



المديرية العامية لل

Circular No. 121 / 2023 Moving Forward

24 -11-1444 H

13 -06-2023

FSCA of Calibration Serum Level 3, Human Precision Control Levels 2 & 3 and Human Assayed Multi-Sera Levels 2 & 3 from Randox Laboratories Ltd.

Source	NCMDR - National Center Medical Device Reporting- SFDA. https://ncmdr.sfda.gov.sa/Secure/CA/CaViewRecall.aspx?caid=4&rid=19549					
Product Calibration Serum Level 3, Human Precision Control Levels 2 & 3 and Human A Sera Levels 2 & 3.						
Description	IVD.					
Manufacturer	Randox Laboratories Ltd.					
Local agent	Mustafa Sultan Science & Industry Co.LLC.					
The affected products	- Calibration Serum Level 3 (CAL2351/CAL10338) - Human Precision Control Levels 2 & 3 (UN1557 & UE1558) - Human Assayed Multi-Sera Levels 2 & 3 (HN1530, HE1532 and HS2611)					
Reason	-Refer to "Table 1: Affected Devices" in the attachment for more details.  Updating the reconstituted 2 - 8 °C stability claim for GLDH in Calibrations Serum Level 3, Human Precision Control Levels 2 & 3 and Human Assayed Multi-Sera Levels 2 & 3 and Alkaline Phosphatase in Calibration Serum Level 3.					
Action	<ol> <li>Customers should be aware of the updated information of the above products stability in the attachment.</li> <li>Contact the local agent for remedial action.</li> </ol>					
comments	Healthcare professionals are encouraged to report any adverse events Suspected to be associate with the above device or any other medical device to Department of Medical Device Control through the E-mail: <a href="Med-device@moh.gov.om">Med-device@moh.gov.om</a>					

Dr. Mohammed Hamdan Al Rubaie

**Director General** 









## RANDOX Customer Notification

Randox Laboratories Ltd 55 Diamond Road Crumlin United Kingdom BT29 4QY technical.services@randox.com Tel: +44 (0) 28 9445 1070

Date Issued: 17 May 23

Complaint Reference: REC662

Action Type: Device Modification

#### Reason for Notification:

In line with the Requirements and Implementation of the *In Vitro* Diagnostic Devices Regulations (IVDR) and the continuous monitoring of the performance and stability claims of our Quality Control (QC) products, we aim to provide the most accurate and up-to-date information on our Instructions for Use (IFUs). For this reason, we have updated the reconstituted 2 - 8 °C stability claim for GLDH in Calibrations Serum Level 3, Human Precision Control Levels 2 & 3 and Human Assayed Multi-Sera Levels 2 & 3 and Alkaline Phosphatase in Calibration Serum Level 3.

#### Calibration Serum Level 3 (CAL2351/CAL10338)

- GLDH reconstituted stability has been reduced from 7 days to 1 day when stored at 2-8°C.
- Alkaline Phosphatase reconstituted stability has been reduced from 7 days to 3 days when stored at 2-8°C.

Human Precision Control Levels 2 & 3 (UN1557 & UE1558) and Human Assayed Multi-Sera Levels 2 & 3 (HN1530, HE1532 and HS2611)

• GLDH reconstituted stability has been reduced from 7 days to 2 days when stored at 2-8°C.

The full storage and stability claim for each product can be found in the lot-specific sheets, accessed through <a href="https://www.randox.com">www.randox.com</a>.

The list of affected lot numbers is available in the table below.

# RANDOX Customer Notification

Randox Laboratories Ltd 55 Diamond Road Crumlin United Kingdom BT29 4QY technical.services@randox.com Tel: +44 (0) 28 9445 1070

**Table 1: Affected Devices** 

	T		T		
Device Name	Catalogue Number	GTIN	Batch / Lot number	Expiry Date	Manufacturing Date
Calibration Serum	CAL10388	N/A	1155UE	28 <sup>th</sup> May 23	19 <sup>th</sup> Apr 21
Level 3	3 CAL2351	05055273200966	1154UE	28 <sup>th</sup> May 23	10 <sup>th</sup> Jun 21
	a a		1155UE	28 <sup>th</sup> May 23	15 <sup>th</sup> Apr 21
u	# U		1156UE	28 <sup>th</sup> May 23	19 <sup>th</sup> Nov 2020
			1225UE	28 <sup>th</sup> Oct 23	7 <sup>th</sup> Sep 21
			1196UE	28 <sup>th</sup> Oct 23	9 <sup>th</sup> Sep 21
Human Precision	UN1557	05055273206807	1400UN	28 <sup>th</sup> May 23	3 <sup>rd</sup> Sep 19
Control Level 2			1440UN	28 <sup>th</sup> May 23	12 <sup>th</sup> Nov 19
2 4 5		£ 4	1459UN	28 <sup>th</sup> Jan 24	20 <sup>th</sup> Mar 2020
Human Precision Control Level 3	UE1558	05055273206791	1088UE	28 <sup>th</sup> Jun 23	9 <sup>th</sup> Aug 19
			1116UE	28 <sup>th</sup> Jun 23	9 <sup>th</sup> Aug 19
Human Assayed	HN1530	05055273203783	1416UN	28 <sup>th</sup> Jun 23	4 <sup>th</sup> Mar 2020
Multi-Sera Level 2			1417UN	28 <sup>th</sup> Jun 23	1 <sup>st</sup> Apr 21
			1489UN	28 <sup>th</sup> May 24	20 <sup>th</sup> Apr 21
			1496UN	28 <sup>th</sup> May 24	27 <sup>th</sup> Apr 21
			1497UN	28 <sup>th</sup> May 24	12 <sup>th</sup> May 21
			1502UN	28 <sup>th</sup> Jun 24	20 <sup>th</sup> Jul 21



Randox Laboratories Ltd 55 Diamond Road Crumlin United Kingdom BT29 4QY technical.services@randox.com

Tel: +44 (0) 28 9445 1070

Human Assayed	HE1532	05055273203608	1102UE	28 <sup>th</sup> Jul 23	4 <sup>th</sup> Mar 2020
Multi-Sera Level 3			1103UE	28 <sup>th</sup> Jul 23	22 <sup>nd</sup> Mar 21
			1104UE	28 <sup>th</sup> Jul 23	8 <sup>th</sup> Jul 23
			1222UE	28 <sup>th</sup> Dec 23	31 <sup>st</sup> May 21
			1173UE	28 <sup>th</sup> Jun 24	3 <sup>rd</sup> Jun 21
			1174UE	28 <sup>th</sup> Jun 24	20 <sup>th</sup> Apr 21
			1223UE	28 <sup>th</sup> Apr 25	23 <sup>rd</sup> Sep 21
			1224UE	28 <sup>th</sup> Apr 25	23 <sup>rd</sup> Sep 21
Human Assayed	HS2611	05055273203813	578618	28 <sup>th</sup> Jun 24	27 <sup>th</sup> Sep 21
Multi-Sera Levels 2 & 3					

#### Action to be taken:

Transmission of Customer Notification: Send a copy of the notification to all affected customers and to those who need to be aware within the organisation.

Complete and return the response form (12187-QA) to <u>technical.services@randox.com</u> within five working days.

Please accept our apologies for any inconvenience caused. Thank you for your patience and understanding. If you have any questions or concerns, please contact Randox Technical Services.